{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:14:16Z","timestamp":1794359656763,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018720","name":"Advanced Accelerator Applications","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Peptide receptor radionuclide therapy (PRRT) using [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATATE has been shown to effectively prolong progression free survival in grade 1\u20132 gastroenteropancreatic neuroendocrine tumours (GEP-NET), but is less efficacious in patients with extensive liver metastases. The aim was to investigate whether tumour uptake in liver metastases can be enhanced by intra-arterial administration of [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATATE into the hepatic artery, in order to improve tumour response without increasing toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twenty-seven patients with grade 1\u20132 GEP-NET, and bi-lobar liver metastases were randomized to receive intra-arterial PRRT in the left or right liver lobe for four consecutive cycles. The contralateral liver lobe and extrahepatic disease were treated via a \u201csecond-pass\u201d effect and the contralateral lobe was used as the control lobe. Up to three metastases (&gt;\u20093\u00a0cm) per liver lobe were identified as target lesions at baseline on contrast-enhanced CT. The primary endpoint was the tumour-to-non-tumour (T\/N) uptake ratio on the 24 h post-treatment [<jats:sup>177<\/jats:sup>Lu]Lu-SPECT\/CT after the first cycle. This was calculated for each target lesion in both lobes using the mean uptake. T\/N ratios in both lobes were compared using paired-samples <jats:italic>t<\/jats:italic>-test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Findings<\/jats:title>\n                <jats:p>After the first cycle, a non-significant difference in T\/N uptake ratio was observed: T\/N<jats:sub>IA<\/jats:sub>\u2009=\u200917\u00b74 vs. T\/N<jats:sub>control<\/jats:sub>\u2009=\u200916\u00b72 (<jats:italic>p<\/jats:italic>\u2009=\u20090\u00b7299). The mean increase in T\/N was 17% (1\u00b717; 95% CI [1\u00b700; 1\u00b737]). Of all patients, 67% (18\/27) showed any increase in T\/N ratio after the first cycle.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Intra-arterial [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATATE is safe, but does not lead to a clinically significant increase in tumour uptake.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06467-y","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T08:02:15Z","timestamp":1698480135000},"page":"1121-1132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA)"],"prefix":"10.1007","volume":"51","author":[{"given":"S. C.","family":"Ebbers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. W.","family":"Barentsz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M. V.","family":"de Vries-Huizing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. W. J.","family":"Versleijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. G.","family":"Klompenhouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E. T.","family":"Tesselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P. M.","family":"Stokkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Brabander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Moelker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"van Leeuwaarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L. J.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J. A. T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G. E. H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"key":"6467_CR1","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1530\/EJE-12-0418","volume":"168","author":"C Lepage","year":"2013","unstructured":"Lepage C, Bouvier AM, Faivre J. Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours. Eur J Endocrinol. 2013;168:R77\u201383. https:\/\/doi.org\/10.1530\/EJE-12-0418.","journal-title":"Eur J Endocrinol"},{"key":"6467_CR2","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1677\/ERC-10-0152","volume":"17","author":"MB Niederle","year":"2010","unstructured":"Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17:909\u201318. https:\/\/doi.org\/10.1677\/ERC-10-0152.","journal-title":"Endocr Relat Cancer"},{"key":"6467_CR3","doi-asserted-by":"publisher","first-page":"6876","DOI":"10.7150\/jca.32381","volume":"10","author":"E Les\u00e9n","year":"2019","unstructured":"Les\u00e9n E, Granfeldt D, Berthon A, Dinet J, Houchard A, Myrenfors P, et al. Treatment patterns and survival among patients with metastatic gastroenteropancreatic neuroendocrine tumours in Sweden-a population-based register-linkage and medical chart review study. J Cancer. 2019;10:6876\u201387. https:\/\/doi.org\/10.7150\/jca.32381.","journal-title":"J Cancer"},{"key":"6467_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/ONCOLO\/OYAC049","volume":"27","author":"MB Sonbol","year":"2022","unstructured":"Sonbol MB, Mazza GL, Mi L, Oliver T, Starr J, Gudmundsdottir H, et al. Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: a SEER database analysis. Oncologist. 2022;27:573\u20138. https:\/\/doi.org\/10.1093\/ONCOLO\/OYAC049.","journal-title":"Oncologist"},{"key":"6467_CR5","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","volume":"15","author":"A Frilling","year":"2014","unstructured":"Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8-21. https:\/\/doi.org\/10.1016\/S1470-2045(13)70362-0.","journal-title":"Lancet Oncol"},{"key":"6467_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177 Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"6467_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","volume":"30","author":"DJ Kwekkeboom","year":"2003","unstructured":"Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417\u201322. https:\/\/doi.org\/10.1007\/s00259-002-1050-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6467_CR8","doi-asserted-by":"publisher","unstructured":"Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020;1\u201311. https:\/\/doi.org\/10.1007\/s00259-020-04709-x.","DOI":"10.1007\/s00259-020-04709-x"},{"key":"6467_CR9","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr 3 ]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124\u201330. https:\/\/doi.org\/10.1200\/JCO.2007.15.2553.","journal-title":"J Clin Oncol"},{"key":"6467_CR10","doi-asserted-by":"publisher","unstructured":"Ebbers S, Barentsz M, Braat A, Lam M. Intra-arterial peptide receptor radionuclide therapy for neuroendocrine tumor liver metastases. Dig Dis Interv. 2019;1. https:\/\/doi.org\/10.1055\/s-0038-1676300.","DOI":"10.1055\/s-0038-1676300"},{"key":"6467_CR11","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-10-0004","volume":"16","author":"C Kratochwil","year":"2010","unstructured":"Kratochwil C, Giesel FL, Lopez-Benitez R, Schimpfky N, Kunze K, Eisenhut M, et al. intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res. 2010;16:2899\u2013905. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0004.","journal-title":"Clin Cancer Res"},{"key":"6467_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1530\/ERC-11-0144","volume":"18","author":"C Kratochwil","year":"2011","unstructured":"Kratochwil C, L\u00f3pez-Ben\u00edtez R, Mier W, Haufe S, Isermann B, Kauczor H-U, et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer. 2011;18:595\u2013602. https:\/\/doi.org\/10.1530\/ERC-11-0144.","journal-title":"Endocr Relat Cancer"},{"key":"6467_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/cbr.2013.1552","volume":"29","author":"SE Pool","year":"2014","unstructured":"Pool SE, Kam BLR, Koning GA, Konijnenberg M, ten Hagen TLM, Breeman WAP, et al. [111 In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy. Cancer Biother Radiopharm. 2014;29:179\u201387. https:\/\/doi.org\/10.1089\/cbr.2013.1552.","journal-title":"Cancer Biother Radiopharm"},{"key":"6467_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13063-019-3888-0","volume":"21","author":"SC Ebbers","year":"2020","unstructured":"Ebbers SC, Braat AJAT, Moelker A, Stokkel MPM, Lam MGEH, Barentsz MW. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials. 2020;21:141. https:\/\/doi.org\/10.1186\/s13063-019-3888-0.","journal-title":"Trials"},{"key":"6467_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105:295\u2013309. https:\/\/doi.org\/10.1159\/000475526.","journal-title":"Neuroendocrinology"},{"key":"6467_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/J.HELIYON.2020.E05267","volume":"6","author":"M Tamal","year":"2020","unstructured":"Tamal M. Intensity threshold based solid tumour segmentation method for Positron Emission Tomography (PET) images: a review. Heliyon. 2020;6: e05267. https:\/\/doi.org\/10.1016\/J.HELIYON.2020.E05267.","journal-title":"Heliyon"},{"key":"6467_CR17","doi-asserted-by":"publisher","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S-150S.\u00a0https:\/\/doi.org\/10.2967\/jnumed.108.057307","DOI":"10.2967\/jnumed.108.057307"},{"key":"6467_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"6467_CR19","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-10-1970","volume":"17","author":"C Brogsitter","year":"2011","unstructured":"Brogsitter C, Faulhaber D, Kotzerke J. Intraarterial treatment of GEP NET: 68Ga-DOTATOC SUV cannot predict 90Y-DOTATOC uptake. Clin Cancer Res. 2011;17:2065\u20132065. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1970.","journal-title":"Clin Cancer Res"},{"key":"6467_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2967\/JNUMED.119.241273","volume":"62","author":"C Lawhn-Heath","year":"2021","unstructured":"Lawhn-Heath C, Fidelman N, Chee B, Jivan S, Armstrong E, Zhang L, et al. Intraarterial peptide receptor radionuclide therapy using 90Y-DOTATOC for hepatic metastases of neuroendocrine tumors. J Nucl Med. 2021;62:221\u20137. https:\/\/doi.org\/10.2967\/JNUMED.119.241273.","journal-title":"J Nucl Med"},{"key":"6467_CR21","doi-asserted-by":"publisher","first-page":"20210403","DOI":"10.1259\/BJR.20210403","volume":"94","author":"P Thakral","year":"2021","unstructured":"Thakral P, Sen I, Das SS, Manda D, CB V, Malik D. Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease. Br J Radiol. 2021;94:20210403. https:\/\/doi.org\/10.1259\/BJR.20210403.","journal-title":"Br J Radiol."},{"key":"6467_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi JC, Sch\u00e4r J-C, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging. 2000;27:273\u201382. https:\/\/doi.org\/10.1007\/s002590050034.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6467_CR23","doi-asserted-by":"publisher","first-page":"936","DOI":"10.2967\/jnumed.108.061457","volume":"50","author":"B Waser","year":"2009","unstructured":"Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009;50:936\u201341. https:\/\/doi.org\/10.2967\/jnumed.108.061457.","journal-title":"J Nucl Med"},{"key":"6467_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.nucmedbio.2009.11.008","volume":"37","author":"I Velikyan","year":"2010","unstructured":"Velikyan I, Sundin A, Eriksson B, Lundqvist H, S\u00f6rensen J, Bergstr\u00f6m M, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass. Nucl Med Biol. 2010;37:265\u201375. https:\/\/doi.org\/10.1016\/j.nucmedbio.2009.11.008.","journal-title":"Nucl Med Biol"},{"key":"6467_CR25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1309\/AJCPQ55SKOCYFZHN","volume":"143","author":"C Shi","year":"2015","unstructured":"Shi C, Gonzalez RS, Zhao Z, Koyama T, Cornish TC, Hande KR, et al. Liver metastases of small intestine neuroendocrine tumorski-67 heterogeneity and world health organization grade discordance with primary tumors. Am J Clin Pathol. 2015;143:398\u2013404. https:\/\/doi.org\/10.1309\/AJCPQ55SKOCYFZHN.","journal-title":"Am J Clin Pathol"},{"key":"6467_CR26","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1097\/PAS.0B013E31821A0696","volume":"35","author":"Z Yang","year":"2011","unstructured":"Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35:853\u201360. https:\/\/doi.org\/10.1097\/PAS.0B013E31821A0696.","journal-title":"Am J Surg Pathol"},{"key":"6467_CR27","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2967\/JNUMED.121.262491","volume":"63","author":"EJPA Vonken","year":"2022","unstructured":"Vonken EJPA, Bruijnen RCG, Snijders TJ, Seute T, Lam MGEH, de Keizer B, et al. Intraarterial administration boosts 177Lu-HA-DOTATATE accumulation in salvage meningioma patients. J Nucl Med. 2022;63:406\u20139. https:\/\/doi.org\/10.2967\/JNUMED.121.262491.","journal-title":"J Nucl Med"},{"key":"6467_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1470-2045(20)30027-9","volume":"21","author":"AJAT Braat","year":"2020","unstructured":"Braat AJAT, Bruijnen RCG, van Rooij R, Braat MNGJA, Wessels FJ, van Leeuwaarde RS, et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 2020;21:561\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(20)30027-9.","journal-title":"Lancet Oncol"},{"key":"6467_CR29","doi-asserted-by":"publisher","unstructured":"Ebbers SC, Brabander T, Tesselaar MET, Hofland J, Braat MNGJA, Wessels FJ, et al. Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy. EJNMMI Res. 2022;12. https:\/\/doi.org\/10.1186\/S13550-022-00880-4.","DOI":"10.1186\/S13550-022-00880-4"},{"key":"6467_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/S00259-020-05004-5","volume":"48","author":"RV Parghane","year":"2021","unstructured":"Parghane RV, Ostwal V, Ramaswamy A, Bhandare M, Chaudhari V, Talole S, et al. Long-term outcome of \u201cSandwich\u201d chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease. Eur J Nucl Med Mol Imaging. 2021;48:913\u201323. https:\/\/doi.org\/10.1007\/S00259-020-05004-5.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06467-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06467-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06467-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T08:05:17Z","timestamp":1708502717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06467-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,28]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["6467"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06467-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,28]]},"assertion":[{"value":"15 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University Medical Centre Utrecht (Aug 2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}